ArticleFrontiers in medicine2026
Pathological mechanisms of long non-coding RNA FOXD2-AS1 promoting osteosarcoma mediated by the COI-1/OCN/Runx-2 signaling pathway.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Osteosarcoma (OS) is the most common primary malignant bone tumor in children and adolescents. Despite three decades of research efforts, no significant improvement in patient survival rates has been achieved, highlighting the urgent need for in-depth investigation into its pathogenesis to develop novel therapeutic strategies and more effective drugs. FOXD2-AS1, a long non-coding RNA, has been implicated in the prognosis and survival of various cancers, but its role in OS remains underexplored. This study therefore aimed to investigate the functional involvement of FOXD2-AS1 in OS progression and to evaluate a biocompatible delivery system for its in vitro and in vivo application. Methods: We synthesized mPEG-PDPA hydrogel via free radical polymerization of 2-(diisopropylamino)ethyl methacrylate (PDA) and polyethylene glycol monomethyl ether acrylate (mPEG-AC), and employed this hydrogel as a delivery vehicle for FOXD2-AS1. The biocompatibility and safety of the empty hydrogel were first validated through both Results and Discussion: Our results demonstrated that the mPEG-PDPA hydrogel itself was non-toxic and reliable as a delivery vehicle. Functionally, FOXD2-AS1 promoted alkaline phosphatase (ALP) release and exacerbated the inflammatory response, thereby accelerating the development and deterioration of OS. Mechanistically, FOXD2-AS1 activated the F-box protein Coronatine Insensitive 1 homolog (COI-1)/OCN/Runx-2 signaling pathway, as confirmed by qPCR and Western blot. Transcriptome analysis further revealed that this process involved changes in cell migration, apoptosis, and cell cycle regulation, with CPS1-IT1, ANKRD10-IT1, TBC1D3P1-DHX40P1, and RGS5 identified as key associated genes. Collectively, our findings provide new insights into the pathological mechanisms of OS and offer valuable data support for future therapeutic strategy development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.